WallStSmart

Evotec SE ADR (EVO)vsTeva Pharma Industries Ltd ADR (TEVA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 2299% more annual revenue ($17.23B vs $718.32M). TEVA leads profitability with a 2.9% profit margin vs -25.2%. TEVA appears more attractively valued with a PEG of 1.04. TEVA earns a higher WallStSmart Score of 42/100 (D).

EVO

Hold

42

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.38

TEVA

Hold

42

out of 100

Grade: D

Growth: 2.7Profit: 6.0Value: 4.3Quality: 3.5
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EVOUndervalued (+89.5%)

Margin of Safety

+89.5%

Fair Value

$33.26

Current Price

$1.32

$31.94 discount

UndervaluedFair: $33.26Overvalued

Intrinsic value data unavailable for TEVA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVO1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

TEVA2 strengths · Avg: 8.5/10
Market CapQuality
$50.14B9/10

Large-cap with strong market position

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Areas to Watch

EVO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$600.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-28.6%2/10

ROE of -28.6% — below average capital efficiency

TEVA4 concerns · Avg: 2.5/10
Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

P/E RatioValuation
99.9x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : EVO

The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : TEVA

The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.

Bear Case : EVO

The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : TEVA

The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.

Key Dynamics to Monitor

EVO profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

EVO carries more volatility with a beta of 1.31 — expect wider price swings.

EVO is growing revenue faster at 0.6% — sustainability is the question.

TEVA generates stronger free cash flow (121M), providing more financial flexibility.

Bottom Line

EVO scores higher overall (42/100 vs 42/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evotec SE ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?